BioCentury
ARTICLE | Clinical News

Mepolizumab: Phase III started

November 5, 2012 8:00 AM UTC

GlaxoSmithKline began the 32-week double-blind, placebo-controlled, international Phase III MEA115588 trial to evaluate 75 mg IV mepolizumab and 100 mg subcutaneous mepolizumab every 4 weeks for 8 dos...